A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for The Treatment of Anaplastic Thyroid Cancer
Principal Investigator
Eric Sherman, MD
Status
Terminated
Date Opened To Accrual
October 28 2010
Date Closed to Accrual
December 30 2016
Date of Study Termination
May 20 2022
Disease Site
Head and Neck [HN]
Head and Neck
Phase
II
Developmental Therapeutics
No
Primary Objective
To evaluate the safety of IMRT, paclitaxel, and pazopanib suspension
To evaluate and compare overall survival at 1 year from study registration.
Patient Population
Pathologically (histologically or cytologically) proven diagnosis of anaplastic thyroid cancer (a diagnosis that is noted to be "consistent with anaplastic thyroid cancer" with the presence of a thyroid mass is acceptable)
The Phase II Component is open to accrual.
Target Accrual
121
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.